Skip to content

Metabolic

PYY3-36

Also called Peptide YY(3-36)

InjectableEvidence AEvery day
Half-life
0.15hours
Typical vial
5 / 10mg
Research amounts
10–50mcg

per administration

Common schedule
Every day
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

The human evidence for PYY3-36 used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded1units dialled
Concentration
1.67mg/mL
Volume per draw
0.01mL

Requested 0.006 mL

Units to dial
1

Requested 0.6

Doses per cartridge
300

0.6 units is between clicks. The nearest setting is 1, which delivers 16.7 mcg instead of 10 mcg.

Vial label

Copy this into your label printer.

Published research contexts for PYY3-36 describe 1050 mcg per administration. Descriptive only, not a recommendation.

Roughly 8–10 minutes; the decay chart is largely illustrative here.

A gut hormone and Y2 receptor agonist studied for reduced food intake. The human evidence used intravenous infusion (Batterham, Nature 2002 and NEJM 2003); no subcutaneous schedule is established, so no schedule table is shown.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
0.98× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
1hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • Batterham RL et al., Nature 2002;418:650Intravenous PYY3-36 infusion reduced food intake in a controlled study of volunteers.
  • Batterham RL et al., NEJM 2003;349:941Intravenous infusion lowered energy intake across lean and obese subjects; the route is infusion, not subcutaneous.

Next steps